Ryvu Therapeutics Company Description

Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology.

Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.

In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology.

The company has a research collaboration with Ncage Therapeutics Limited to develop next-generation antibody-drug conjugate (ADC) platform.

Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Ryvu Therapeutics S.A.

Country	Poland
Founded	2007
Industry	Biotechnology
Sector	Healthcare
Employees	270
CEO	Pawel Przewiezlikowski

Contact Details

Address: Leona Henryka Sternbacha 2 Kraków, 30-394 Poland
Phone	48 12 314 0200
Website	ryvu.com

Stock Details

Ticker Symbol	RVU
Exchange	Warsaw Stock Exchange
Fiscal Year	January - December
Reporting Currency	PLN
ISIN Number	PLSELVT00013
SIC Code	2836

Key Executives

Name	Position
Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.	Founder, President of the Management Board and Chief Executive Officer
Dr. Krzysztof Daniel Brzózka M.B.A., Ph.D.	Executive Vice President, Chief Scientific Officer and Vice President of the Management Board
Dr. Kamil Sitarz M.B.A., Ph.D.	Chief Operating Officer and Member of the Management Board
Vatnak Vat-Ho M.B.A.	Chief Business Officer and Member of Management Board
Dr. Hendrik Nogai M.D.	Chief Medical Officer and Member of Management Board
Paulina Wolanin	Human Resources Manager